BioCryst Pharmaceuticals (BCRX) Stock Forecast, Price & News

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioCryst Pharmaceuticals in the last twelve months. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BCRX shares.
View BCRX analyst ratings or view top-rated stocks.

7 Wall Street analysts have issued 1-year target prices for BioCryst Pharmaceuticals' stock. Their BCRX share price forecasts range from $10.00 to $30.00. On average, they predict the company's stock price to reach $15.00 in the next year. This suggests a possible upside of 79.6% from the stock's current price.
View analysts price targets for BCRX or view top-rated stocks among Wall Street analysts.

BioCryst Pharmaceuticals' stock was trading at $11.48 at the beginning of 2023. Since then, BCRX shares have decreased by 27.3% and is now trading at $8.35.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our BCRX earnings forecast.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) posted its quarterly earnings data on Wednesday, May, 3rd. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.30) by $0.02. The biotechnology company had revenue of $68.80 million for the quarter, compared to the consensus estimate of $71.44 million. BioCryst Pharmaceuticals's revenue was up 37.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.40) earnings per share.

ETFs with the largest weight of BioCryst Pharmaceuticals (NASDAQ:BCRX) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA), ETFMG Treatments Testing and Advancements ETF (GERM), Virtus LifeSci Biotech Products ETF (BBP), ALPS Medical Breakthroughs ETF (SBIO), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Principal Healthcare Innovators ETF (BTEC) and First Trust Small Cap Growth AlphaDEX Fund (FYC).

9 employees have rated BioCryst Pharmaceuticals Chief Executive Officer Jon P. Stonehouse on Glassdoor.com. Jon P. Stonehouse has an approval rating of 40% among the company's employees. This puts Jon P. Stonehouse in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 64.0% of employees surveyed would recommend working at BioCryst Pharmaceuticals to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other BioCryst Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), El Pollo Loco (LOCO), Advanced Micro Devices (AMD), Idera Pharmaceuticals (IDRA), OPKO Health (OPK), Dynavax Technologies (DVAX), La Jolla Pharmaceutical (LJPC), Novavax (NVAX), Sorrento Therapeutics (SRNE) and VBI Vaccines (VBIV).

BioCryst Pharmaceuticals trades on the NASDAQ under the ticker symbol "BCRX."

BioCryst Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.85%), State Street Corp (6.03%), Avoro Capital Advisors LLC (5.52%), Pictet Asset Management SA (2.97%), Assenagon Asset Management S.A. (2.64%) and Fisher Asset Management LLC (2.26%). Insiders that own company stock include Alane P Barnes, Anthony Doyle, George B Abercrombie, George B Abercrombie, Helen M Thackray, Jon P Stonehouse, Michael L Jones, Nancy J Hutson, Vincent Milano, William P Sheridan and Yarlagadda S Babu.
View institutional ownership trends.

Shares of BCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BCRX stock can currently be purchased for approximately $8.35.

BioCryst Pharmaceuticals (NASDAQ:BCRX) has a market capitalization of $1.58 billion and generates $289.68 million in revenue each year. The biotechnology company earns $-247,120,000.00 in net income (profit) each year or ($1.21) on an earnings per share basis.

The company employs 358 workers across the globe.

BioCryst Pharmaceuticals' mailing address is 4505 EMPEROR BOULEVARD SUITE 200, DURHAM NC, 27703. The official website for the company is www.biocryst.com. The biotechnology company can be reached via phone at (919) 859-1302, via email at investorrelations@biocryst.com, or via fax at 919-859-1314.